The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

被引：120

作者：

Greene, Stephen J. ^{[1
]}

Gheorghiade, Mihai ^{[1
]}

Borlaug, Barry A. ^{[2
]}

Pieske, Burkert ^{[3
]}

Vaduganathan, Muthiah ^{[4
]}

Burnett, John C., Jr. ^{[2
]}

Roessig, Lothar ^{[5
]}

Stasch, Johannes-Peter ^{[6
]}

Solomon, Scott D. ^{[7
]}

Paulus, Walter J. ^{[8
]}

Butler, Javed ^{[9
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA

[2] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN USA

[3] Med Univ Graz, Dept Cardiol, Graz, Austria

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA

[5] Bayer Pharma AG, Berlin, Germany

[6] Bayer HealthCare, Cardiol Res, Wuppertal, Germany

[7] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[8] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Physiol, Inst Cardiovasc Res VU, Amsterdam, Netherlands

[9] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA

来源：

JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2013年 / 2卷 / 06期

关键词：

cGMP; heart failure; phosphodiesterase; 5; preserved ejection fraction; soluble guanylate cyclase; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE SYNTHASE; IMPROVES EXERCISE CAPACITY; PULMONARY-HYPERTENSION; NATRIURETIC PEPTIDE; PHOSPHODIESTERASE-5; INHIBITION; DIASTOLIC DISTENSIBILITY; ENDOTHELIAL DYSFUNCTION; SODIUM-NITROPRUSSIDE; CONTRACTILE RESPONSE;

D O I：

10.1161/JAHA.113.000536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：11

共 50 条

[31] Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Borlaug, Barry A.
Paulus, Walter J.
EUROPEAN HEART JOURNAL, 2011, 32 (06) : 670 - +
[32] Heart failure with preserved ejection fraction
Rigolli, Marzia
Whalley, Gillian A.
JOURNAL OF GERIATRIC CARDIOLOGY, 2013, 10 (04) : 369 - 376
[33] Heart failure with preserved ejection fraction
Reda, S.
Motloch, L. J.
Hoppe, U. C.
KARDIOLOGE, 2011, 5 (03): : 237 - 243
[34] Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction
Konstantinou, Dimitrios M.
Chatzizisis, Yiannis S.
Giannoglou, George D.
PHARMACOLOGY & THERAPEUTICS, 2013, 140 (02) : 156 - 166
[35] Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction
Kim, Mi-Na
Park, Seong-Mi
HEART FAILURE CLINICS, 2021, 17 (03) : 463 - 482
[36] From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
Franssen, Constantijn
Chen, Sophia
Hamdani, Nazha
Paulus, Walter J.
HEART, 2016, 102 (04) : 320 - 330
[37] Heart Failure with Preserved Ejection Fraction
Meyer, Adam
Kerrigan, Martin
HOSPITAL MEDICINE CLINICS, 2015, 4 (03) : 283 - 296
[38] Heart failure with mid-range ejection fraction and with preserved ejection fraction
Petutschnigg, J.
Edelmann, F.
HERZ, 2018, 43 (05) : 392 - 405
[39] Prolonged QRS in Heart Failure With Preserved Ejection Fraction Risk Marker and Therapeutic Target?
Kelly, Jacob P.
Daubert, James P.
JACC-HEART FAILURE, 2016, 4 (06) : 487 - 489
[40] Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
Guazzi, Marco
Naeije, Robert
CIRCULATION-HEART FAILURE, 2021, 14 (04) : E007840

← 1 2 3 4 5 →